EuroPharma has signed an exclusive multi-year contract with DolCas Biotech (DolCas) for the use of absorbency BCM-95 curcumin and specialised BosPure boswellia in multiple EuroPharma formulations.
Reportedly, the exclusive distribution territory for these clinically-studied ingredients includes health food store channel and professional channel, involving allopathic doctors, chiropractors, naturopathic doctors, and clinics.
BCM-95 is highly absorbable curcumin. Human clinical data indicates that BCM-95 is up to 10 times more absorbable than curcumin 95% and 6.3 times more absorbable than curcumin with lecithin and piperine.
BosPure boswellia is beta-boswellic acid free, and standardised to contain 10-15% AKBA (Acetyl-11-Keto-Beta-Boswellic Acid), which enhances its targeted impact on the body’s natural anti-inflammatory response.
EuroPharma has agreed to support the marketing, promotion and distribution of BCM-95 and BosPure formulas with a targeted multi-million-dollar marketing investment.
Terry Lemerond, president and founder of EuroPharma, said: “We are proud to enter into this agreement, not only because BCM-95 curcumin and BosPure boswellia are in supplement research, but because we are proud to represent such a fine partner in DolCas Biotech.”
The company said that further research is being conducted on BCM-95 and BosPure and results will be published in near future.